168 related articles for article (PubMed ID: 37357301)
21. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
22. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
[TBL] [Abstract][Full Text] [Related]
23. Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil.
Samara M; Levine SZ; Yoshida K; Goldberg Y; Cipriani A; Efthimiou O; Iwatsubo T; Leucht S; Furakawa TA
J Alzheimers Dis; 2021; 82(3):1075-1084. PubMed ID: 34120898
[TBL] [Abstract][Full Text] [Related]
24. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
27. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
[TBL] [Abstract][Full Text] [Related]
28. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
[TBL] [Abstract][Full Text] [Related]
29. Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale-Sum of Boxes.
Grober E; Qi Q; Kuo L; Hassenstab J; Perrin RJ; Lipton RB
J Alzheimers Dis; 2021; 80(1):185-195. PubMed ID: 33492286
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
31. Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.
Wessels AM; Rentz DM; Case M; Lauzon S; Sims JR
Alzheimers Dement (N Y); 2022; 8(1):e12312. PubMed ID: 35676941
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
33. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
[TBL] [Abstract][Full Text] [Related]
34. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
[TBL] [Abstract][Full Text] [Related]
35. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
[TBL] [Abstract][Full Text] [Related]
36. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
38. Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors.
Ackley SF; Wang J; Chen R; Power MC; Allen IE; Glymour MM
Alzheimers Dement; 2024 Feb; 20(2):1149-1155. PubMed ID: 37904290
[TBL] [Abstract][Full Text] [Related]
39. Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Jamalian S; Dolton M; Chanu P; Ramakrishnan V; Franco Y; Wildsmith K; Manser P; Teng E; Jin JY; Quartino A; Hsu JC;
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1029-1042. PubMed ID: 37101394
[TBL] [Abstract][Full Text] [Related]
40. Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).
Oh ES; Rosenberg PB; Rattinger GB; Stuart EA; Lyketsos CG; Leoutsakos JS
J Am Geriatr Soc; 2021 Apr; 69(4):955-963. PubMed ID: 33382921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
